Acumen Pharmaceuticals Inc. has provided an update on its ongoing clinical development programs targeting early Alzheimer's disease $(AD)$. The company highlighted sabirnetug (ACU193), a monoclonal antibody highly selective for toxic amyloid beta oligomers, which has shown positive results in Phase 1 clinical trials involving AD patients. Enrollment for the Phase 2 trial, designed as a registration-quality study with 540 participants, was completed in March 2025, and topline results are expected in late 2026. The presentation also detailed Acumen's Enhanced Brain Delivery (EBDTM) program, which is focused on developing blood-brain barrier-penetrant, oligomer-targeted antibodies. Non-clinical data from the EBD program are anticipated in early 2026. The company reports a strong financial position to support its clinical development plans. You can access the full presentation through the link below.